NCT00800956View on ClinicalTrials.gov

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

PHASE1CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Healthy

Interventions

DRUG

[14C]-esreboxetine

Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine

Trial Locations (1)

98415

Pfizer Investigational Site, Tacoma

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY